Female Infertility: Seven-Market Drug Forecast and Market Analysis

Table of Contents

Table of Contents

1 Female Infertility: Executive Summary

• 1.1 Female infertility will grow moderately during the forecast period, reaching sales of $2.3 billion in 2033.
• 1.2 R&D strategies focused largely on improved versions of current drugs.
• 1.3 Despite major progress in treating patients, unmet needs exist in the space.
• 1.4 Sparse pipeline, but potential new addition highly intriguing to physicians
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Diminished ovarian reserve and ovulation disorders.
  • 3.1.2 Endometriosis
  • 3.1.3 Fallopian tube abnormalities/pelvic adhesions
  • 3.1.4 Uterine factors
  • 3.1.5 Unexplained infertility
  • 3.1.6 Other factors

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology.
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods.
  • 4.4.3 Forecast assumptions and methods: diagnosed incident cases of female infertility.
  • 4.4.4 Forecast assumptions and methods: total prevalent cases of impaired fecundity.
  • 4.4.5 Forecast assumptions and methods: total prevalent cases of impaired fecundity.
  • 4.4.6 Forecast assumptions and methods: total prevalent cases of female infertility by etiologic factors.
• 4.5 Epidemiological forecast for female infertility and impaired fecundity (2023-33)
  • 4.5.1 Diagnosed incident cases of female infertility.
  • 4.5.2 Age-specific diagnosed incident cases of female infertility
  • 4.5.3 Total prevent cases of female infertility.
  • 4.5.4 Age-specific total prevalent cases of female infertility
  • 4.5.5 Total prevent cases of female infertility by major etiologic factors.
  • 4.5.6 Total prevalent cases of impaired fecundity
  • 4.5.7 Age-specific total prevalent cases of impaired fecundity
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact.
  • 4.6.3 Limitations of analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview
• 6.2 Ovulation induction
  • 6.2.1 Clomiphene citate and aromatase inhibitors
  • 6.2.2 Gonadotropins
• 6.3 Assisted reproductive technology (ART)
  • 6.3.1 Gonadotropins
  • 6.3.2 GnRH agonists
  • 6.3.3 GnRH antagonists
  • 6.3.4 Dopamine agonist receptors
  • 6.3.5 Luteal phase support

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Patient-friendlier progesterone administration for luteal phase support.
• 7.3 Novel treatments for poor responders
• 7.4 Enhancing IVF outcomes.
• 7.5 Development of non-injectable fertility medication
• 7.6 Access to fertility treatment

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Long-acting FSH analogue
  • 8.1.2 Pre-filled pen injection devices
• 8.2 Clinical trial design
  • 8.2.1 Current clinical trial design
  • 8.2.2 Incomplete reporting of outcomes

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report.
  • 13.4.1 KOLs
• 13.5 Primary research - Prescriber survey
• 13.6 About the Authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy area director
  • 13.6.3 Epidemiologist
  • 13.6.4 Reviewers epidemiologist
  • 13.6.5 Vice president of disease intelligence and epidemiology
  • 13.6.6 Global head of pharma research, analysis, and competitive intelligence
• Contact Us